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Abstract 
The pharmacy profession has undergone substantial change over the last two to 
three decades. Whilst medicine supply still remains a central function, pharmacist’s 
roles and responsibilities have become more clinical and patient-focused. In 
community (primary care), pharmacists have become important providers of 
healthcare as Western healthcare policy advocates patient self-care. This has 
resulted in pharmacists taking on greater responsibility in managing minor illness 
and the delivery of public health interventions. These roles require pharmacists to 
more fully use their clinical skills, and often involve diagnosis and therapeutic 
management. Community pharmacists are now, more than ever before, in a position 
to identify, record and report medication safety incidents. However, current research 
suggests that diagnostic ability of community pharmacists is questionable and they 
infrequently report to local or national schemes. The aim of this paper is to highlight 
current practice and suggest ways in which community pharmacy can more fully 
contribute to patient safety.  
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Key Points 
Community pharmacists’ scope of practice is widening which demands greater use 
of clinical and diagnostic skills to provide more patient focused clinical services. 
Patient advocacy and clinical accountability need strengthening within pharmacy 
education to allow practitioners to take responsibility for their patients, and ensure 
patient safety through better vigilance 
As community pharmacists embark on this role transition there is an opportunity to 
engender a culture of reporting that is supported by organisational change to ensure 
sustainability 
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Community Pharmacists in Pharmacovigilance: Can Improved Diagnostic 
Ability Translate to Better Vigilance? 
 
1 Introduction 
 
Healthcare systems across the world, and in particular Western healthcare systems, 
have undergone major reforms in response to political and economic pressures [1-6]. 
This has resulted in attempts to maximise existing resources, both financial and 
staffing, to improve delivery of effective and efficient healthcare [7-8]. Healthcare 
policies of many countries now encourage the public to take control of their own 
health. Community pharmacists have been identified as a very accessible 
professional group that can optimise patient use of medicines and facilitate patient 
self-care [9-11]. This will require community pharmacists to combine their traditional 
role of medicine supply (and medicines expertise) [12, 13] with the need to provide 
additional patient-focused services [14-16]. This re-alignment of job role has started 
to see an expansion in their scope of practice, involving public health services [17-
19], inclusion in to national systems to report adverse drug reactions [20], and 
granting of prescribing rights [21-23]. 
 
The self-care concept has been supported by governments making more medicines 
freely available. Most medicines that have been ‘switched’ from prescription control 
are to relieve signs and symptoms associated with acute episodes of illness but 
recently for the management of long-term conditions (e.g. statins and tamsulosin) 
have also been made available..  
 
Australia, Germany, UK, and the US are seen as world leaders in medicine switching 
[24]. For example, over 90 prescription medicines have been made non-prescription 
in the UK between 1983 and 2013; in the US, from 1976 to 2003, there were 71 
prescription to over-the-counter (OTC) switches [25]. Community pharmacists 
therefore find themselves the custodians of an increasing arsenal of medicines which 
can be used to manage a wider range of signs and symptoms. This affords 
pharmacists opportunities to monitor for adverse events associated with these 
products as well as identifying drug-induced signs and symptoms.  
 
2 Diagnostic Ability of Community Pharmacists 
 
The role of ‘responding to symptoms’ has been associated with community 
pharmacy practice for decades but with increased medicine deregulation (including 
European-wide deregulation, for example orlistat [26]) and role expansion, 
pharmacists need to be well schooled in how to diagnose. However, limited research 
has assessed community pharmacists’ ability to be a good diagnostician. Pharmacy 
researchers have primarily assessed what questions pharmacists ask and the 
actions they take when dealing with standardised patient scenarios, [27, 28] or what 
influences pharmacist selection of non-prescription medicines [29]. Only recently has 
exploratory research begun to investigate the process by which they make a 
diagnosis [30, 31]. Data suggest that community pharmacists rely heavily on 
protocol-driven questioning that may lead to mis-diagnosis. Indeed consumer 
organisations have criticised the diagnostic ability of pharmacists when assessed 
using mystery shoppers [32-25]. In pharmacy’s defence, the underpinning 
knowledge and skills required to diagnose from a patients presenting signs and 
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symptoms are relatively recent introductions to pharmacy undergraduate curricula 
[36], and even when elements of diagnosis are covered, for example, physical 
examination (which is a pre-requisite for course accreditation in the US) it is not 
necessarily in the context of making a diagnosis [37]. In many European curricula it 
still does not feature [38]. Given the development of contemporary pharmacy 
practice and current research findings there seems to be a need to equip current and 
future pharmacists with better diagnostic skills. In the UK, this ‘skills shortage’ of 
practitioners has been partially recognised with the launch of a national learning and 
development framework on consultation skills in April 2014 [39]. 
 
3 Community Pharmacist Contribution to Pharmacovigilance 
 
Many of the roles and responsibilities being afforded to community pharmacists 
require greater use of clinical skills, especially those involving consultation, diagnosis 
and therapeutic intervention [40]. What is unknown is will these facilitated self-care 
models effect how community pharmacists contribute to medicines safety? Looking 
at current practice it appears that reporting by community pharmacists is low, 
especially when it is voluntary. Two examples are used here for illustration. ADR 
reporting by pharmacists is now well established in many countries [20], and where 
data are available, community pharmacists tend to be worse at reporting than their 
hospital colleagues. [41-43] Barriers to poor reporting are well documented [44-45], 
but lack of financial incentive has been additionally cited by community pharmacists 
[46]. A further example is drawn from the UK National Reporting and Learning 
System (NRLS), which captures patient safety incidents for England and Wales. A 
2006 study found that pharmacy staff were unlikely to report adverse events, 
regardless of severity. A lack of understanding about reporting and mistrust about its 
purpose were given as reasons for non-reporting [47]. This situation appears not to 
have markedly improved in that NRLS statistics for 2011-12 showed community 
pharmacists reported 1343 incidents compared to 3967 by primary care doctors [48]. 
Incidents reported by community pharmacists were almost entirely based (96% of 
reports) on medicine safety issues (compared to 18% for doctors), which does 
highlight the highly focused nature of pharmacy reporting. 
When incentivised, it appears community pharmacists are more likely to document 
and report medicine safety issues. Two new medicine adherence services (New 
Medicines Services in the UK and Home Medicines Review in Australia) allow 
pharmacists to assess patient understanding and use of new and established 
medicines [49, 50]. Both services require each patient consultation to be 
documented and form the basis for remuneration and require pharmacists to report 
on medication safety issues. In the first nine months after the New Medicines Service 
was launched, ADR reporting increased by 120% [51]. 
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4 Improving Pharmacovigilance from Community Pharmacies 
Current medication/patient safety incident reporting rates are low. There is a need 
within community pharmacy to improve reporting - and of course learning, from such 
incidents. The key question is how community pharmacists’ can be encouraged to 
report more given that role expansion will provide increased diagnostic opportunity. 
We believe that changes need to be made both within the pharmacy profession and 
to existing healthcare structures.  
4.1 The Profession 
Pharmacy has, and in some countries still is, a predominantly science-based course, 
yet if pharmacy education is to keep pace with current and future changes in practice 
then curricula have to adapt to become more patient focused. This will not 
necessarily be about providing knowledge – for example pharmacovigilance is 
reasonably well understood and covered at undergraduate level [52-54]. Teaching 
focus needs to be patient centred and will require students to develop attributes 
which reinforce the need to put patient welfare first. Pharmacy could learn from other 
professions, such as medicine in this regard [55]. From such foundations, concepts 
of clinical reasoning, patient safety and clinical accountability can be instilled. 
Concepts can then be translated in to practice by actions which include diagnosis, 
shared decision making, documentation and reporting. To ensure this behaviour 
becomes routine, pharmacy students should have greater exposure to first hand 
clinical practice. The extent to which this is happening internationally varies 
enormously; but in general the experiential opportunities afforded to pharmacy 
students is much less than other healthcare students. This exposure to practice and 
working with others in multidisciplinary environments will foster and consolidate a 
more patient focused approach to care – something that is not always apparent in 
pharmacy curricula. 
Inevitably, educational changes take time to percolate in to clinical practice, creating 
a need for postgraduate opportunities to bridge this gap. One such example is 
courses to become an independent prescriber where clinical accountability and 
diagnostic ability have greater prominence [56]. Research undertaken with 
prescribing pharmacists has largely focused on their attitudes toward this new role 
but one study found that prescribing pharmacists were more likely to report 
suspected ADRs than nurse prescribers [57]. Whether training to be a prescriber 
affects attitude toward pharmacovigilance is unknown; more studies are required to 
establish if independent prescribers routinely incorporate patient safety reporting in 
to their practice. If this is the case then there is a compelling argument to instruct 
undergraduates in a similar fashion. 
Finally, it must be acknowledged that potential barriers to practice change are 
pharmacists themselves. Work has highlighted time, money and lack of interest as 
constraints yet when models have been trialed to remove such obstacles sustained 
practice change has not resulted [58, 59]. Evidence also suggests that pharmacists 
are reluctant to move away from a supply function and shy away from taking 
responsibility for the patient. [60-62]. 
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4.2 Organisational Change 
The environment in which community pharmacists work hampers their ability to 
better contribute to medication and patient safety. New ways of working need to be 
incorporated in to clinical practice. Changes in the way services are delivered and 
integrated in existing healthcare structures need consideration. Having access to 
shared care records would be one way in which primary healthcare services could 
be more closely aligned. Access to records would enable, and may encourage, 
community pharmacists to document, report and reflect on their activities when 
facilitating patient self-care. This could be further strengthened by introducing formal 
referral mechanisms to medical practitioners following pharmacist diagnosis to allow 
follow-up and determine outcomes. This may necessitate patient registration with a 
named community pharmacy. Registration at a community pharmacy is not unknown 
as exemplified by the Scottish minor ailments service [63]. Such changes need to be 
incentivised. Evidence suggests that incentives do influence community pharmacists’ 
activity. When providing contracted services (through government or medical 
insurance) the remuneration models need to move away from prescription supply to 
activity that has reward for providing more patient-focused activities. Such models 
are being introduced, although the inclusion of pharmacovigilance-type activities is 
low [50, 64, 65]. For private transactions (e.g. over-the-counter consultations) 
changes to legislation may hold the key to increased documentation and incident 
reporting even though there is evidence that educational intervention around ADRs 
has a positive effect on reporting rates [66]. In all likelihood a combination of 
incentive and legal compulsion will be required. Regardless of approach taken the 
success and speed of adoption will depend on strong leadership, appropriate 
resource and creation of sustainable infrastructures. 
5 Conclusion 
Community pharmacy is in transition from a medicine supply service to providing 
cognitive services as self-care policies in Western societies become more prominent. 
The workforce is currently poorly prepared to take on some of these roles that 
involve the ability to diagnose and accept clinical accountability. To ensure patient 
safety the profession needs to develop a patient centred, medicines focused culture 
that embraces reporting medicine safety issues. This must be supported by 
healthcare policy that allows better integration of community pharmacy services. 
Ethical standards 
The manuscript does not contain clinical studies or patient data. 
Conflict of Interest 
We state that we have full control of all primary data and that we agree to allow the 
journal to review their data if requested.  
David Brown is an honorary research fellow of the UK Drug Safety Research Unit, 
Southampton. This is an associate organisation of the University of Portsmouth. 
Funding: None  
Competing interests: None 
7 
 
References  
1. Commonwealth of Australia. Building a 21st Century Primary Health 
Care System: Australia’s First National Primary Health Care Strategy. 
Canberra, ACT: Department of Health and Ageing, 2010 [online]. Available 
from URL: 
http://www.health.gov.au/internet/yourhealth/publishing.nsf/Content/report-
primaryhealth. [Accessed 2014 Jan 23] 
2. Commonwealth of Australia. A National Health and Hospitals 
Network for Australia’s Future: Delivering The Reforms. Canberra, ACT: 
Commonwealth of Australia, 2010 [online]. Available from URL: 
http://www.health.gov.au/internet/yourhealth/publishing.nsf/Content/DeliveringT
heReforms. [Accessed 2014 Jan 23] 
3. Black N. Can England’s NHS survive? N Engl J Med 2013 Jul 
4;369(1):1-3.  
4. Keyhani S, Falk R, Howell EA, Bishop T, Korenstein D. Overuse and 
systems of care: a systematic review. Med Care 2013;51(6):503-8.  
5. Marchildon G. Canada: Health system review. Health Syst Transit 
2013;15(1):1-179. 
6. 2012 – the NZ Health Strategy, Health Targets, Better Sooner More 
convenient [online]. Available from URL: 
http://www.health.govt.nz/system/files/documents/publications/better-sooner-
more-convenient-health-care_0.pdf [Accessed 2014 Jan 23] 
7. NHS and social care workforce: meeting our needs now and in the 
future? [online]. Available from URL: 
http://www.kingsfund.org.uk/sites/files/kf/field/field_publication_file/perspectives
-nhs-social-care-workforce-jul13.pdf [Accessed 23 Jan 2014] 
8. 2009 Health Workforce New Zealand. [online]. Available from URL: 
http://healthworkforce.govt.nz/annual-plans [Accessed 2014 Jan 23] 
9. Paudyal V, Hansford D, Cunningham S, Stewart D. Pharmacy assisted 
patient self care of minor ailments: A chronological review of UK health policy 
documents and key events 1997-2010. Health Policy 2011:101:3 253-259. 
10. Pharmacy Guild of Australia [online]. Available from URL: 
http://www.guild.org.au/docs/default-source/public-documents/news-and-
events/2013-federal-election/vital-facts-on-community-pharmacy-
june2013_441678_2.pdf [Accessed 2014 May 26] 
11. Planning a research study? – think community pharmacy RPS [online]. 
Available from URL: http://www.rpharms.com/news-story-downloads/think-
pharmacy---promotional-leaflet.pdf  [Accessed 2014 Jan 23] 
12. Jesson JK, Langley CA, Wilson KA, Hatfield K. Science or practice? 
UK undergraduate experiences and attitudes to the MPharm degree. Pharm 
World Sci 2006; 28: 278–283. 
8 
 
13. NHS Choices – Pharmacy services. [online]. Available from URL: 
http://www.nhs.uk/NHSEngland/AboutNHSservices/pharmacists/Pages/pharma
cistsandchemists.aspx. [Accessed 2014 Jan 23] 
14. Department of Health. Pharmacy in England: Building on Strengths – 
Delivering the Future. London: Crown Copyright, 2008 [online]. Available from 
URL: 
http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/en/Consultations/Cl
osedconsultations/DH_087324. [Accessed 2014 Jan 23] 
15. Canadian Pharmacists Association Task Force on a Blueprint for 
Pharmacy. Blueprint for Pharmacy: Designing the Future Together. Ottawa: 
CPhA, 2008 [online]. Available from URL: 
http://www.pharmacists.ca/index.cfm/pharmacy-in-canada/blueprint-for-
pharmacy/ [Accessed 2014 Jan 23] 
16. Pharmaceutical Society of New Zealand. Focus on the Future: a Ten-
year Vision for Pharmacists in New Zealand 2004–2014. Wellington: 
Pharmaceutical Society of New Zealand, 2004 [online]. Available from URL: 
http://psnz.org.nz/public/home/documents/10_yea_plan.pdf [Accessed 2014 
Jan 23] 
17. Healthy Lives, Healthy People – our strategy for public health in 
England. Department of Health (2010) [online]. Available from URL: 
https://www.gov.uk/government/publications/healthy-lives-healthy-people-our-
strategy-for-public-health-in-england. [Accessed 2014 Jan 23] 
18. Guide for public health – Partnering with Pharmacists in the Prevention 
and Control of Chronic Diseases. National Center for Chronic Disease 
Prevention and Health Promotion [online]. Available from URL: 
http://www.cdc.gov/dhdsp/programs/nhdsp_program/docs/pharmacist_guide.pd
f. [Accessed 23 Jan 2014] 
19. Claim and Confirmation for Home Medicines Review Service [online]. 
Available from URL: http://www.medicareaustralia.gov.au/provider/pbs/fifth-
agreement/files/4915-1303en.pdf [Accessed 2014 Jan 23] 
20. van Grootheest K, Olsson S, Couper M, Jong-van den Berg L.  
Pharmacists’ role in reporting adverse drug reactions in an International 
perspective. Pharmacoepidemiol Drug Saf 2004;13:457-64. 
21. Emmerton L, Marriott J, Bessell T, Nissen L, Dean L. Pharmacists and 
prescribing rights: review of international developments. J Pharm Pharm Sci 
2005;8(2):217-25. 
22. Pharmacy Council of New Zealand. Pharmacist prescribers [online]. 
Available from URL: 
http://www.pharmacycouncil.org.nz/cms_display.php?st=1&sn=232. [Accessed 
2014 Jan 23] 
23. California’s pharmacist provider status bill passes state Senate. 
[online]. Available from URL: 
http://www.pharmacist.com/CEOBlog/california%E2%80%99s-pharmacist-
provider-status-bill-passes-state-senate [Accessed 2014 May 23] 
9 
 
24. World self-medication Industry. SWITCH. Prescription to non-
prescription medicines switch. WSMI 2009 [online]. Available from URL: 
http://www.wsmi.org/pdf/wsmi_switchbrochure.pdf  [Accessed 2014 Jan 23] 
25. Wertheimer AI, Santella TM. Medication errors associated with over-
the-counter drugs; prevalence and reduction strategies.  J Pharmaceut Finance 
Econ Pol 2007;15:109–44. 
26. European Medicines Agency – Alli [online]. Available from URL: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medici
nes/000854/human_med_000641.jsp  [Accessed 2014 May 26] 
27. Lansam GD, Kropff MA. Community pharmacists’ assessments and 
recommendations for treatment in four scenarios. Ann Pharmacother 
1998;32:409-416. 
28. Horsley E, Rutter P, Brown D. Evaluation of Community Pharmacists’ 
Recommendations to Standardized Patient Scenarios. Ann Pharmacother 
2004:38;1080-1085. 
29. Hanna L, Hughes CM. 'First, do no harm': Factors that influence 
pharmacists making decisions about over-the-counter medication: A qualitative 
study in Northern Ireland. Drug Saf 2010;33(3):245-255. 
30. Iqbal N, Rutter P. Community Pharmacists Reasoning When Making a 
Diagnosis: A think-aloud study think aloud IJPP 2013; 21: Supplement 2, 17-8. 
31. Rutter P, Patel J. Decision Making by Community Pharmacists When 
Making an Over-the-counter Diagnosis in Response to a dermatological 
presentation. SelfCare 2013;4:125-133. 
32. Consumers’ Association. Pharmacists: how reliable are they? Which 
Way to Health? 1991; (12):191-4.  
33. Consumers’ Association. Vital checks are still not being made. Which 
Way to Health? 1994;(12):196. 
34. Consumers’ Association. Counter advice. Which Way to Health? 
1999;(3):22-25.  
35. Which? Pharmacies get test of own medicine.[online]. Available from 
URL: 
www.which.co.uk/news/2008/09/pharmacies-get-test-of-own-medicine-157330/. 
[Accessed 2014 Jan 23] 
36. Future pharmacists Standards for the initial education and training 
of pharmacists. [online]. Available from URL: 
http://www.pharmacyregulation.org/sites/default/files/GPhC_Future_Pharmacist
s.pdf 
37. Accreditation Council for Pharmacy Education. Accreditation Standards 
and Guidelines for the Professional Program in Pharmacy Leading to the 
Doctor of Pharmacy Degree. [online]. Available from URL: https://www.acpe-
accredit.org/pdf/FinalS2007Guidelines2.0.pdf [Accessed 2014 Jan 23] 
38. Pharmine –Pharmacy Education in Europe [online]. Available from 
URL: 
http://enzu.pharmine.org/media/filebook/files/PHARMINE%20Final%20Report%
20Public%20Part.pdf   [Accessed 2014 Jan 23] 
39. CPPE Consultation skills; meeting the new practice standards for 
pharmacy [online]. Available from URL: 
http://www.cppe.ac.uk/learning/Details.asp?TemplateID=Consult-W-
03&Format=W&ID=26&EventID=- [Accessed 2014 Jan 23] 
10 
 
40. Brown D, Portlock J, Rutter P. Services to support the Healthy Living 
Pharmacy - a literature review. Int J Clin Pharm 2012; 34(3): 399-409.   
41. Hadi MA. Impact of pharmacist recruitment on ADR reporting: 
Malaysian experience. Southern Med Review 2011;4:102. 
42. Kimura T, Matsushita Y, Kao Yang YH, Choi NK, Park BJ. 
Pharmacovigilance systems and databases in Korea, Japan, and Taiwan.  
Pharmacoepidemiol Drug Saf 2011;20:1237-45. 
43. Granas AG, Buajordet M, Stenberg-Nilsen H, Harg P, Horn AM. 
Pharmacists’ attitudes towards the reporting of suspected adverse drug 
reactions in Norway. Pharmacoepidemiol Drug Saf 2007;16:429-434. 
44. Pharmacist reporting of serious adverse drug events to the Food and 
Drug Administration. Gavaza P, Brown CM, Lawson KA, Rascati KL, Steinhardt 
M, Wilson JP.J Am Pharm Assoc (2003). 2012 Sep-Oct;52(5):e109-12. 
45. Su C, Ji H, Su Y. Hospital pharmacists’ knowledge and opinions 
regarding adverse drug reaction reporting in Northern China. 
Pharmacoepidemiol Drug Saf 2010;19:217-222. 
46. Tobaiqy M, Stewart D, Helms PJ, Bond C, Lee AJ, Bateman N, McCaig 
D, McLay J. A pilot study to evaluate a community pharmacy–based monitoring 
system to identify ADRs associated with paediatric use. Eur J Clin Pharmacol 
2010;66(6):627-32. 
47. Ashcroft DM, Morecroft C, Parker D, Noyce PR. Likelihood of reporting 
adverse events in community pharmacy: an experimental study. Qual Saf 
Health Care 2006;15:48–52. 
48. NRLS Quarterly Data Workbook up to September 2012 [online]. 
Available from URL: http://www.nrls.npsa.nhs.uk/resources/type/data-
reports/?entryid45=135212 [Accessed 2014 Jan 23] 
49. Pharmaceutical Services Negotiating Committee. New Medicines 
Service [online]. Available from URL: 
http://psnc.org.uk/services-commissioning/advanced-services/nms/#directions 
[Accessed 2014 Jan 23] 
50. Claim and Confirmation for Home Medicines Review Service [online]. 
Available from URL: http://www.medicareaustralia.gov.au/provider/pbs/fifth-
agreement/files/4915-1303en.pdf [Accessed 2014 Jan 23] 
51. Jadeja M, McCreedy C. Positive effect of new medicine service on 
community yellow card reporting. Pharm J 2012; 289:159. 
52. Smith MP, Webley SD. Pharmacovigilance teaching in UK 
undergraduate pharmacy programmes. Pharmacoepidemiol Drug Saf 2013; 22: 
223–228. 
53. Sardas SS, Akici AA, Dagistanli SD. The knowledge and attitude of the 
undergraduate students in the faculty of pharmacy towards pharmacovigilance. 
Drug Saf 2010; 33(10): 930-931. 
54. Elkalmi RM, Hassali MA, Ibrahim MI, Widodo RT, Efan QM, Hadi MA. 
Pharmacy students' knowledge and perceptions about pharmacovigilance in 
Malaysian public universities. Am J Pharm Ed 2011; 7595): Article 96. 
55. American Board of Internal Medicine. Project Professionalism; 1995 
[online]. Available from URL: 
http://www.abim.org/pdf/publications/professionalism.pdf.  [Accessed 2014 May 
23] 
11 
 
56. General Pharmaceutical Council. Approval of courses [online]. 
Available from URL: http://www.pharmacyregulation.org/education/approval-
courses [Accessed 2014 Jan 23] 
57. Stewart D, MacLure K, Paudyal V, Hughes C, Courtney M, McLay J.  
Non-medical prescribers and pharmacovigilance: participation, competence 
and future needs. Int J Clin Pharm 2013;35:268-74. 
58. Kroger E, Moisan J, Gregoire JP. Billing for cognitive services: 
understanding Quebec pharmacists’ behaviour. Ann Pharmacother 
2000;34:309-316. 
59. Chan P, Grindrod KA, Bougher D, Pasutto FM, Wilgosh C, Eberhart G, 
Tsuyuki R. A systematic review of remuneration systems for clinical pharmacy 
services. Can Pharm J 2009; 141(2):102-112. 
60. Rosenthal M. Austin Z, Tsuyuki RT. Are pharmacists the ultimate 
barrier to pharmacy practice change? Can Pharm J 2010; 143(1):37-42. 
61. Austin Z, Gregory PAM, Martin JC. Negotiation of interprofessional 
culture shock: the experiences of pharmacists who become physicians. J 
Interprof Care 2007;21:83-93.   
62. Blake KB, Madhavan SS. Perceived barriers to provision of medication 
therapy management services (MTMS) and the likelihood of a pharmacist to 
work in a pharmacy that provides MTMS. Ann Pharmacother 2010;44:424-31. 
63. National Services Scotland. Practitioner services [online]. Available 
from URL: http://www.psd.scot.nhs.uk/pharmacists/patient-registration.html 
[Accessed 2014, May 23]. 
64. Gray B. Ontario pharmaceutical opinion program. Can Pharm J 2013; 
146(6): 329–334.  
65. Richardson E, Pollock AM. Community pharmacy: moving from 
dispensing to diagnosis and treatment. Brit Med J 2010;340:1066-1068. 
66. Gonzalez-Gonzalez C, Lopez-Gonzalez E, Herdeiro MT, Figueiras A. 
Strategies to Improve adverse drug reaction reporting: a critical and systematic 
review. Drug Saf 2013;36(5):317-28. 
 
